-
1.发明授权公开(公告)号：US10005730B2
公开(公告)日：2018-06-26
申请号：US14969454
申请日：2015-12-15
Inventor： Maria Alessandra Alisi , Nicola Cazzolla , Isabella Coletta , Patrizia Dragone , Guido Furlotti , Barbara Garofalo , Angelo Guglielmotti , Giorgina Mangano , Caterina Maugeri
IPC: C07D209/88
CPC classification number: C07D209/88
Abstract: The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin E2 (PGE2), for instance inflammatory processes, pain, fever, tumours, Alzheimer's disease and atherosclerosis.
-
2.发明授权公开(公告)号：US09655906B2
公开(公告)日：2017-05-23
申请号：US14803384
申请日：2015-07-20
Inventor： Maria Alessandra Alisi , Nicola Cazzolla , Guido Furlotti , Beatrice Garrone , Gabriele Magaro , Giorgina Mangano
IPC: A61K31/4985 , C07D487/04 , A61K31/551
CPC classification number: A61K31/551 , A61K31/4985 , C07D487/04
Abstract: Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them.The tricyclic indazole compound has the following general formula (I): in which R1, R2, L1, L2, X1, X2, X3, X4, X5, Y, W, m, and n have the meanings stated in the description.
-
公开(公告)号：US20140378532A1
公开(公告)日：2014-12-25
申请号：US14376299
申请日：2013-02-21
Inventor： Vincenzo Russo , Elisa Liberati , Nicola Cazzolla
IPC: A61K47/48 , A61K31/713 , C08B37/18
CPC classification number: A61K47/4823 , A61K31/713 , A61K31/716 , A61K47/61 , A61K2201/324 , A61K2201/326 , C08B37/0009 , C08B37/18
Abstract: The present invention relates to glycogen-based cationic polymers, to complexes of the said cationic polymers with anionic compounds, to pharmaceutical compositions comprising the said complexes, and to the use of the said complexes for delivering or transfecting the said anionic compounds to a specific pharmacological target, such as, for instance an organ, a tissue or a cell.
Abstract translation: 本发明涉及基于糖原的阳离子聚合物，所述阳离子聚合物与阴离子化合物的络合物，包含所述复合物的药物组合物，以及所述复合物用于将所述阴离子化合物递送或转染到特定药理学 靶，例如器官，组织或细胞。
-
公开(公告)号：US10160746B2
公开(公告)日：2018-12-25
申请号：US15439172
申请日：2017-02-22
Inventor： Maria Alessandra Alisi , Nicola Cazzolla , Patrizia Dragone , Guido Furlotti , Caterina Maugeri , Rosella Ombrato , Francesca Mancini
IPC: C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/454 , A61K31/4545 , A61K31/506
Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.
-
公开(公告)号：US09700551B2
公开(公告)日：2017-07-11
申请号：US14825261
申请日：2015-08-13
Inventor： Maria Alessandra Alisi , Nicola Cazzolla , Barbara Garofalo , Guido Furlotti , Gabriele Magaro' , Rosella Ombrato , Francesca Mancini
IPC: A61K31/454 , A61K31/4545 , A61K31/5377 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/12 , C07D417/14
CPC classification number: A61K31/454 , A61K31/4545 , A61K31/5377 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.
-
Patent Agency Ranking
公开(公告)号：US20170157121A1
公开(公告)日：2017-06-08
申请号：US15439172
申请日：2017-02-22
Inventor： Maria Alessandra ALISI , Nicola Cazzolla , Patrizia Dragone , Guido Furlotti , Caterina Maugeri , Rosella Ombrato , Francesca Mancini
IPC: A61K31/506 , A61K31/4545 , A61K31/454
CPC classification number: C07D401/12 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D401/14 , C07D405/14 , C07D413/14
Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.
-
公开(公告)号：US09611249B2
公开(公告)日：2017-04-04
申请号：US14373100
申请日：2013-02-07
Inventor： Maria Alessandra Alisi , Nicola Cazzolla , Patrizia Dragone , Guido Furlotti , Caterina Maugeri , Rosella Ombrato , Francesca Mancini
IPC: C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14
CPC classification number: C07D401/12 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D401/14 , C07D405/14 , C07D413/14
Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.
-
8.发明申请NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS 有权作为GLYCOGEN SYNTHASE激酶3β抑制剂的1H-吲哚-3-羧酰胺化合物的新用途公开(公告)号：US20140378455A1
公开(公告)日：2014-12-25
申请号：US14373393
申请日：2013-02-08
Inventor： Maria Alessandra Alisi , Nicola Cazzolla , Barbara Garofalo , Guido Furlotti , Gabriele Magaro' , Rosella Ombrato , Francesca Mancini
IPC: C07D417/14 , C07D405/14 , C07D401/12 , C07D413/14
CPC classification number: A61K31/454 , A61K31/4545 , A61K31/5377 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.
Abstract translation: 1H-吲唑-3-甲酰胺化合物作为糖原合酶激酶3β抑制剂。 本发明涉及用作糖原合酶激酶3β（GSK-33）抑制剂的1H-吲唑-3-甲酰胺化合物及其在治疗GSK-3p相关病症中的用途，例如（i ）胰岛素抵抗障碍; （ii）神经变性疾病; （iii）情绪障碍; （iv）精神分裂症; （v）癌症; （vi）炎症，（vii）物质滥用障碍; 和（viii）癫痫。
-
9.发明授权Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors 有权使用1H-吲唑-3-甲酰胺化合物作为糖原合酶激酶3β抑制剂公开(公告)号：US09163013B2
公开(公告)日：2015-10-20
申请号：US14373393
申请日：2013-02-08
Inventor： Maria Alessandra Alisi , Nicola Cazzolla , Barbara Garofalo , Guido Furlotti , Gabriele Magaro′ , Rosella Ombrato , Francesca Mancini
IPC: A61K31/5377 , A61K31/454 , C07D413/14 , C07D211/68 , C07D417/14 , C07D401/14 , C07D405/14 , C07D401/12
CPC classification number: A61K31/454 , A61K31/4545 , A61K31/5377 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.
Abstract translation: 1H-吲唑-3-甲酰胺化合物作为糖原合酶激酶3β抑制剂。 本发明涉及用作糖原合酶激酶3β（GSK-3＆bgr））抑制剂的1H-吲唑-3-甲酰胺化合物，以及它们在治疗GSK-3和相关病症中的用途，例如， （i）胰岛素抵抗障碍; （ii）神经变性疾病; （iii）情绪障碍; （四）精神分裂症; （v）癌症; （vi）炎症，（vii）物质滥用障碍; 和（viii）癫痫。
-
10.发明申请3-AMINOCARBAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PREPARATION METHOD THEREFOR 审中-公开3-氨基喹唑啉化合物，含有它的药物组合物及其制备方法公开(公告)号：US20160102056A1
公开(公告)日：2016-04-14
申请号：US14969454
申请日：2015-12-15
Inventor： Maria Alessandra Alisi , Nicola Cazzolla , Isabella Coletta , Patrizia Dragone , Guido Furlotti , Barbara Garofalo , Angelo Guglielmotti , Giorgina Mangano , Caterina Maugeri
IPC: C07D209/88
CPC classification number: C07D209/88
Abstract: The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin E2 (PGE2), for instance inflammatory processes, pain, fever, tumours, Alzheimer's disease and atherosclerosis.
Abstract translation: 本发明涉及3-氨基咔唑的新型苯甲酰基衍生物，其含有它们的药物组合物，其制备方法和用于制备可用于治疗或预防相关疾病的药物的用途 产生前列腺素E2（PGE2），例如炎症过程，疼痛，发烧，肿瘤，阿尔茨海默病和动脉粥样硬化。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.036 seconds)
